<DOC>
	<DOCNO>NCT02191826</DOCNO>
	<brief_summary>Clinical proof concept study evaluate SOM0226 efficacy TTR Amyloidosis .</brief_summary>
	<brief_title>Study SOM0226 Familial Amyloid Polyneuropathy</brief_title>
	<detailed_description>This open label interventional Phase IIa proof concept clinical trial design two phase separate washout period 6 week ( Â± 2 week ) , evaluate TTR stabilization activity SOM0226 healthy volunteer ( wild type ) , TTR-FAP patient asymptomatic carrier . - Phase A ( 24 hour ) : SOM0226 single dose - Phase B ( 32 hour ) : SOM0226 multiple dose</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<criteria>Participant willing able give inform consent participation study Male Female , age 18 year time consent Two cohort define TTR variant ( wild type : healthy volunteer ; TTR mutant : asymptomatic carrier document mutation TTR diagnose TTRFAP patient ( stage 1 2 ) undergo pharmacological treatment Vyndaqel Body Mass Index ( BMI ) &gt; 17.5 kg/m2 Female participant child bear potential male participant whose partner child bear potential must willing ensure partner use effective contraception study 2 month thereafter Able ( Investigators opinion ) willing comply study requirement Female participant pregnant , lactate plan pregnancy course study Evidence history clinically significant hepatic disease An ALT AST measurement &gt; 2 time ULN ( Upper Limit Normal ) Scheduled elective surgery procedure require general anaesthesia study Donation blood study within past 4 week Treatment ( study within past 4 week ) prescription investigational drug treatment TTR amyloidosis Treatment NSAIDs ( nonsteroidal antiinflammatory drug ) study within past 4 week . The follow NSAID allow : acetylsalicylic acid , etodolac , ibuprofen , indomethacin , ketoprofen , nabumetone , naproxen , nimesulide , piroxicam sulindac</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>Amyloidosis</keyword>
	<keyword>SOM0226</keyword>
	<keyword>Familiar Amyloid Polyneuropathy</keyword>
</DOC>